Daily FNArena News - Small Caps

Artificial intelligence and some valuable experiences should benefit heart device developer Artrya, Tim Boreham explains

Some cannabis gems are sprouting in the ASX weed patch, but they are hard to find in the haze of hype, Tim Boreham, Editor, The New Criterion reports

In response to a broker’s negative assessment, Judo Capital has provided a surprise trading update that significantly exceeded expectations

Brokers raise valuations for Neuren Pharmaceuticals following positive Phase 2 clinical trial results

Tim Boreham highlights the prospects for cancer treatment biotech Imugene

Despite higher interest rates, Autosports Group is seeing no easing in demand for luxury cars, providing solid revenue growth guidance at its AGM

Tim Boreham highlights how PYC Therapeutics’ gene therapy can address a plethora of genetic afflictions

Tim Boreham highlights the success of Paradigm Biopharmaceuticals’ joint pain drug ahead of a capital raising

Already enthusiastic analysts have lifted their enthusiasm regarding Dropsuite’s outlook following impressive third quarter results

FDA approval for Cyclopharm’s device-as-a-drug is welcome news, Tim Boreham reports